Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

Medical AI Has a ‘Proof Problem’: Only 2.4% of FDA-Approved Devices Backed by Trial Data; Nvidia, Microsoft, Google Face Regulatory Headwinds

by Team Lumida
September 18, 2026
in AI
Reading Time: 4 mins read
A A
0
Medical AI Has a ‘Proof Problem’: Only 2.4% of FDA-Approved Devices Backed by Trial Data; Nvidia, Microsoft, Google Face Regulatory Headwinds
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Medical AI developers and healthcare institutions face a significant gap between lab validation and real-world clinical impact. A Michigan doctor (Kayla Secrest) encountered a sepsis-detection algorithm that triggered alerts for every patient, becoming as ineffective as “the boy who cried wolf.” The tool was rolled out to hundreds of hospitals without extensive real-world testing. Jess Morley (Yale Digital Ethics Centre) notes AI companies focus on “statistical validation” (accuracy) rather than “clinical efficacy” (patient outcomes). “There is really shockingly poor evidence that AI actually makes an impact on patient outcomes.”
  • Regulatory oversight is insufficient: FDA authorized 258 AI medical devices in 2025, with only 2.4% supported by the kind of clinical trial data mandatory for drugs. Stanford research found most AI devices don’t require new clinical trials before approval. Post-market surveillance consists of “sanitised reports written by manufacturers, which have no raw data” (Stephen Gilbert, University of Dresden). Transparency is lacking: companies make specific claims about workflow improvements and cost savings but are under no obligation to disclose training data, methodology, or validation datasets.
  • Generative AI advances (enabled by ChatGPT launch in 2022) have captivated healthcare managers via “the wow factor,” but evidence of benefit-to-harm ratios remains elusive. OpenAI claimed AdventHealth reported 80% reduction in administrative tasks using ChatGPT for Healthcare; Nvidia’s Kimberly Powell cited AI lightening clinician typing burden. However, Eric Topol (Scripps Research) notes most AI leaders show “little appetite” for measuring post-deployment performance. Only in diagnostics/imaging (colonoscopy polyp detection, MRI analysis) is evidence “irrefutable.” Andrew Wong (University of Utah) warns that without transparent development information, individual institutions must test tools—not all have resources.
  • Regulation hasn’t kept pace with AI capability doubling (every 4 months since 2023). MRHA’s Lawrence Tallon advocates for conditional authorisation pending real-world evidence and continuous monitoring. But hospitals—especially rural, understaffed facilities—lack capacity to evaluate bias before deployment. Ziad Obermeyer (UC Berkeley) discovered a risk-stratification tool at his hospital discriminated against minorities and non-English speakers. “The scale at which these things are already being adopted is enormous.” Tightened validation requirements could delay healthcare AI revenue recognition for Nvidia, Microsoft, and Google.

What Happened?

Financial Times “Big Read” published investigation into medical AI’s “proof problem”—the gap between developers’ lab validation and real-world clinical impact. Key findings: AI companies focus on statistical accuracy rather than patient outcome improvements; FDA authorized 258 AI medical devices in 2025, with only 2.4% backed by clinical trial data; post-market surveillance consists of manufacturer reports without raw data; companies make claims about workflow improvements without releasing training data or validation methodology; OpenAI claims AdventHealth achieved 80% administrative time reduction with ChatGPT for Healthcare; Nvidia’s healthcare head cited AI reducing clinician typing burden; regulation has not kept pace with AI capability doubling every 4 months since 2023; hospitals lack resources to evaluate bias; algorithms change continuously, making randomized controlled trials inadequate oversight mechanisms.

Why It Matters?

For patients, the validation gap means AI tools may be deployed at scale without proof they improve outcomes—or may actively harm through bias or alert fatigue. For healthcare institutions, lack of transparency makes it difficult to verify vendor claims about cost savings or workflow improvements. For regulators, the article validates need for post-market surveillance and real-world evidence rather than lab-only validation. For AI chip/software makers (Nvidia, Microsoft, Google), tightened clinical validation requirements could delay healthcare AI adoption, defer revenue recognition, and require increased R&D spending on clinical trials. For healthcare equity, the article highlights risk that biased AI tools could be deployed to millions of patients without evaluation for discriminatory impacts.

What’s Next?

Monitor UK MRHA’s formal adoption of National Commission’s recommendations for conditional authorisation and continuous monitoring—if implemented, could become global standard and delay Nvidia/MSFT/Google healthcare AI deployments. Watch FDA’s pilot programmes (cardiovascular, diabetes, mental health AI models) for real-world evidence generation requirements; if adopted, it would shift approval pathway and extend time-to-revenue for healthcare AI. Track healthcare AI lawsuits; if patients sue hospitals over AI-related harms, it could accelerate regulatory tightening and increase liability exposure for software/chip makers. Monitor hospital AI bias audits; if major systems discover discrimination issues, it will trigger audits across sector and pressure vendors to invest in validation. Also watch Nvidia/Microsoft/Google healthcare AI guidance updates; if companies warn of delayed clinical validation timelines, it could pressure healthcare segment growth forecasts.

Affected Tickers & Coins: NVDA, MSFT, GOOGL

Source: Financial Times

Previous Post

US Stock Futures Little Changed Friday After Thursday’s Post-Fed Rally; Asian Markets Gain on Rate Clarity, AI Narrative Intact

Next Post

OpenAI Breached by Researchers Using Anthropic Tools; Anthropic Discloses 26% of R&D Led by AI in Recursive Self-Improvement Push

Recommended For You

Trump Says the US Could Let Nvidia Sell Blackwell Chips to China in ‘Two Years or Three Years,’ Calling the H200 ‘Semi-Obsolete’ as Congress Moves to Bar Sales for 18 Months

by Team Lumida
6 hours ago

Trump said Nvidia could sell Blackwell chips to China in two or three years, as senators push the AI Overwatch Act to bar such sales for at least...

Read more

Intel Signs Its First Outside Customer for 18A Chips and Names Microsoft as Its First Public Customer for EMIB Packaging, After Losing More Than Half Its Value Since September

by Team Lumida
6 hours ago
Intel Surges 5%, SK Hynix Up 3% on Reports of U.S. Memory Chip Manufacturing Deal to Serve Nvidia and AI Demand

Intel CEO Lip-Bu Tan said the company signed its first outside customer for 18A chips and named Microsoft as its first public EMIB packaging customer.

Read more

China’s Military Is ‘Actively Soliciting’ Nvidia’s Most Advanced Chips for AI-Enabled Military Capabilities, a Congressional Commission Says in Its 2026 Report

by Team Lumida
22 hours ago

A congressional commission said China’s military is seeking advanced Nvidia chips and evading export controls, including via data centers in Malaysia.

Read more

Bipartisan Push to Attach AI Chip Export Limits to the December NDAA Gains Steam After the Huang Affair, With Schumer, Jeffries and Speaker Johnson Backing the AI Overwatch, MATCH and Chip Security Acts

by Team Lumida
1 day ago

Lawmakers from both parties are pushing three chip export bills into the December defense bill after Jensen Huang’s resignation, but time is short.

Read more

Banks Pause a $480 Million Nvidia GPU Loan to Aolani Cloud Tied to ByteDance After New US Licensing Rules for Malaysia and Singapore Data Centers

by Team Lumida
2 days ago
ByteDance Is Buying Custom Chips From Taiwan Because It Cannot Buy Nvidia’s, Which US Rules Permit

Banks paused or reconsidered a $480 million Aolani Cloud loan for Nvidia GPUs tied to ByteDance after new US licensing rules, Bloomberg reported.

Read more

Commerce and Justice Say They Began Investigating Nvidia Partner Megaspeed in 2024, as Critics Ask Why It Kept Getting Chips After Nvidia’s ‘No Sell’ Listing

by Team Lumida
2 days ago

Commerce and Justice said they opened export-control probes into Megaspeed in 2024 and inspected it in June 2025, as critics question how it kept buying chips.

Read more

Nvidia Warns Chip Buyers That the Remote Access Security Act Could Expose Them to US ‘Legal Action’ and Caps Sales to Clouds Renting Over 50% of GPUs to Chinese Firms

by Team Lumida
2 days ago

Nvidia cautioned customers that the proposed Remote Access Security Act could bring US legal action over Chinese cloud access to its chips, CNBC reported.

Read more

Anthropic’s IPO Could Hand 300-Plus Investors a Windfall, With a $1.33 Trillion Valuation About 38% Above Its $965 Billion May Round

by Team Lumida
3 days ago

Anthropic’s IPO, expected to value it at $1.33 trillion or more, is set to reward over 300 investors, from Spark and Menlo to Amazon and Alphabet.

Read more

Commerce Moves to Close the Offshore Data-Center Loophole for Chinese AI Firms and Requires Licenses for Chip Exports to Five Countries, Its First Policy Response to the Nvidia Scandal

by Team Lumida
3 days ago

Commerce issued a rule curbing Chinese firms’ offshore access to Nvidia compute and requiring chip-export licenses for five higher-risk countries.

Read more

Trump Administration Plans to Name Nvidia, OpenAI and More Than Two Dozen AI Firms ‘National Champions’ as the BAI AI ETF Sits 33% Below Its June Record

by Team Lumida
3 days ago
The AI Capex Machine Keeps Roaring — Nvidia’s Manufacturing Partner Hon Hai Crushes Estimates as Server Demand Drowns Out Recession Fears

The Trump administration plans to name more than two dozen AI firms, including Nvidia and OpenAI, US national champions, the WSJ reported.

Read more
Next Post
OpenAI Breached by Researchers Using Anthropic Tools; Anthropic Discloses 26% of R&D Led by AI in Recursive Self-Improvement Push

OpenAI Breached by Researchers Using Anthropic Tools; Anthropic Discloses 26% of R&D Led by AI in Recursive Self-Improvement Push

SoftBank’s $50B SB Energy IPO Data Centre Gamble Pressured by OpenAI’s Delayed IPO; Nvidia Guarantees $105B for Ohio Campus

SoftBank's $50B SB Energy IPO Data Centre Gamble Pressured by OpenAI's Delayed IPO; Nvidia Guarantees $105B for Ohio Campus

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Trump Pushes for Greenland Acquisition, Exploring Business Deals and Military Presence

Trump Opens Second Tariff Front as White House Races to Rebuild Trade Powers

March 13, 2026
Fed’s Kashkari Predicts December Rate Cut

Fed’s Kashkari Predicts December Rate Cut

June 17, 2024
Geopolitical Forces Shape Oil Market Dynamics

Iran’s Oil Revenue Is Drying Up: US Naval Blockade Has Trapped Every Barrel Since Mid-July

September 8, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018